Drug intelligence / Profile preview

PBP1601

Development stage: Preclinical
Lead developer: Prestige Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

PBP1601 is a biosimilar monoclonal antibody developed by Prestige Biopharma (PBK) that targets the Receptor Activator of Nuclear Factor Kappa-B Ligand (RANK-L). It is designed as a biosimilar to denosumab, which is marketed under the brand names Prolia and Xgeva. As a RANK-L neutralizing antibody, PBP1601 inhibits the maturation, function, and survival of osteoclasts, thereby reducing bone resorption and increasing bone mass and strength. The drug is currently in the IND-enabling preclinical development phase for the treatment of osteoporosis and bone metastases.

Other names: denosumab biosimilar

Targets

RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)

Beyond the preview

Go deeper on PBP1601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBP1601.

Explore the full profile